FibroBiologics Competitors and Similar CompaniesClear all

FibroBiologics's competitors and similar companies include Ergomed, Laurus Labs, Kemwell Biopharma and Guizhou Sanli Pharmaceutical.

	FibroBiologics FibroBiologics is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.	Ergomed Ergomed Group is a company that provides drug development services to the pharmaceutical industry.	Laurus Labs Laurus Labs is a pharmaceutical company.	Kemwell Biopharma Kemwell Biopharma is a contract biologic development company.	Guizhou Sanli Pharmaceutical Guizhou Sanli Pharmaceutical (贵州三力制药股份有限公) researches and develops medicinal products.
Founding Date	Founding Date 2021	Founding Date 1997	Founding Date 2005	Founding Date 1980	Founding Date 1995
Type	Type Public	Type Private	Type Public	Type Private	Type Public
Tags	Tags Healthcare clinical research drug development pharma	Tags Healthcare clinical research drug development pharma	Tags Healthcare clinical research drug development pharma	Tags Healthcare clinical research drug development pharma	Tags Healthcare clinical research drug development pharma
Locations	Locations Webster, US HQ	Locations Guildford, GB HQ	Locations Hyderabad, IN HQ Hamburg, DE Turkapally, IN Visakhapatnam, IN Visakhapatnam, IN Visakhapatnam, IN Visakhapatnam, IN see more	Locations Bengaluru, IN HQ	Locations An Shun Shi, CN HQ
Employees	Employees 10	Employees 1,800	Employees 5,75359% increase	Employees 5341% decrease	Employees 2,85225% increase
Valuation ($)	Valuation ($) 97 m	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 796.5 m
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) £145.3m (FY, 2022)	Revenue (est.) ₹68.1b (FY, 2026)	Revenue (est.) N/A	Revenue (est.) ¥2.1b (FY, 2024)
Cost of goods	Cost of goods N/A	Cost of goods £86.1m (FY, 2022)	Cost of goods ₹27b (FY, 2026)	Cost of goods N/A	Cost of goods ¥650m (FY, 2024)
Gross profit	Gross profit N/A	Gross profit £60.3m (FY, 2022)	Gross profit ₹41.7b (FY, 2026)	Gross profit N/A	Gross profit ¥1.5b (FY, 2024)
Net income	Net income ($18.6m) (FY, 2025)	Net income £15m (FY, 2022)	Net income ₹8.9b (FY, 2026)	Net income N/A	Net income ¥279.8m (FY, 2024)